Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

Study Overview

This phase I trial studies the side effects and the best dose of veliparib and dinaciclib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment. Veliparib and dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Description

Phase 1 Trial of ABT-888 and SCH727965 in Patients with Advanced Solid Tumors

  • ClinicalTrials.gov Identifier: NCT01434316
  • Protocol Number: 11-144
  • Principal Investigator: Gerburg Wulf
  • Principal Investigator: Central PIO

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000